Extended Low-Dose Apixaban and Superficial Vein Thrombosis: Post Hoc Analysis of the HI-PRO Randomized Clinical Trial

Sina Rashedi; Mariana Pfeferman; Arvind Pandey; Darsiya Krishnathasan; Candrika D Khairani; Antoine Bejjani; Ruth H Morrison; Heather Hogan; Junyang Lou; John Fanikos; Nicole Porio; Lisa Rosenbaum; Piotr S Sobieszczyk; Zhou Lan; Marie Gerhard-Herman; Umberto Campia; Samuel Z Goldhaber; Behnood Bikdeli; Gregory Piazza

doi:10.1001/jamacardio.2026.0151

Extended Low-Dose Apixaban and Superficial Vein Thrombosis: Post Hoc Analysis of the HI-PRO Randomized Clinical Trial

JAMA Cardiol. 2026 May 1;11(5):478-480. doi: 10.1001/jamacardio.2026.0151.

Authors

Sina Rashedi¹, Mariana Pfeferman¹, Arvind Pandey², Darsiya Krishnathasan¹, Candrika D Khairani¹, Antoine Bejjani^{1

3}, Ruth H Morrison¹, Heather Hogan¹, Junyang Lou^{1

2}, John Fanikos^{1

4}, Nicole Porio¹, Lisa Rosenbaum⁵, Piotr S Sobieszczyk², Zhou Lan^{1

6}, Marie Gerhard-Herman², Umberto Campia^{1

2}, Samuel Z Goldhaber^{1

2}, Behnood Bikdeli^{1

2

7}, Gregory Piazza^{1

2}

Affiliations

¹ Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
³ Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
⁴ Department of Pharmacy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
⁵ Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
⁶ Brigham and Women's Hospital, Center for Clinical Investigation, Harvard Medical School, Boston, Massachusetts.
⁷ Yale New Haven Hospital/Yale Center for Outcomes Research and Evaluation, New Haven, Connecticut.

PMID: 41904964
PMCID: PMC13034163 (available on 2027-03-29)
DOI: 10.1001/jamacardio.2026.0151

No abstract available

Plain language summary

This post hoc analysis of the Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism (HI-PRO) randomized clinical trial investigates the impact of extended low-dose apixaban on symptomatic superficial vein thrombosis events in patients with provoked venous thromboembolism and enduring risk factors.